文献速递神经免疫

复发缓解型多发性硬化患者停用疾病修饰治疗后的疾病再激活

Disease Reactivation After Cessation of Disease-Modifying Therapy in Patients With Relapsing-Remitting Multiple Sclerosis.
PubMed 文献 · Neurology · 2022-08-17

该回顾性队列研究基于MSBase和OFSEP两个大型观察性多发性硬化登记库,纳入14,213例停用疾病修饰治疗且随访12个月的复发缓解型多发性硬化患者,评估停药后疾病活动复发率。结果显示不同治疗停药后再激活速率不同,那他珠单抗和芬戈莫德停药后复发高峰分别为2-4个月和1-2个月,启动后续治疗可降低复发和残疾累积风险。

要点

  • 那他珠单抗停药后2-4个月年化复发率升至0.47,芬戈莫德停药后1-2个月为0.80。
  • 那他珠单抗停药后2-4个月内启动后续治疗可减小疾病再激活幅度(平均ARR差值0.15)。
  • 启动后续治疗降低复发风险(HR 0.76)和残疾累积风险(HR 0.73)。

核心结论

  • 停用不同多发性硬化治疗后的疾病再激活速率不同,未治疗队列中复发活动高峰在1至10个月之间。
  • 作者认为停用抗 trafficking 治疗(那他珠单抗和芬戈莫德)后应尽量缩短未治疗间期。

研究设计与样本

  • 回顾性队列研究,数据来自MSBase和OFSEP两个大型观察性多发性硬化登记库。
  • 纳入停用疾病修饰治疗并随访后续12个月的复发缓解型多发性硬化患者,共14,213例,18,029个符合条件的治疗停用时段,涉及7种治疗。

主要发现

  • 那他珠单抗停药后2个月年化复发率开始升高(第2-4个月ARR 0.47,95%CI 0.43-0.51)。
  • 芬戈莫德停药后复发率总体升高(第1-2个月ARR 0.80,95%CI 0.70-0.89)。
  • 其他治疗停药后疾病再激活幅度低,但在停药后1-10个月启动另一治疗可进一步降低。
  • 复发的预测因素包括停药前一年较高的复发率、女性、较年轻年龄和较高EDSS评分。
  • 启动后续治疗降低复发风险(HR 0.76,95%CI 0.72-0.81)和残疾累积风险(HR 0.73,95%CI 0.65-0.80)。

关键数值与推荐

  • 那他珠单抗停药后2-4个月内启动后续治疗减小疾病再激活幅度(平均ARR差值0.15,95%CI 0.08-0.22)。
  • 芬戈莫德停药后1-2个月内启动新治疗使复发率稳定更快(平均ARR差值0.14,95%CI -0.01至0.29)。

临床怎么用

  • 作者认为停用那他珠单抗和芬戈莫德后应尽量缩短未治疗间期。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: To evaluate the rate of return of disease activity after cessation of multiple sclerosis (MS) disease-modifying therapy. METHODS: This was a retrospective cohort study from 2 large observational MS registries: MSBase and OFSEP. Patients with relapsing-remitting MS who had ceased a disease-modifying therapy and were followed up for the subsequent 12 months were included in the analysis. The primary study outcome was annualized relapse rate in the 12 months after disease-modifying therapy discontinuation stratified by patients who did, and did not, commence a subsequent therapy. The secondary endpoint was the predictors of first relapse and disability accumulation after treatment discontinuation. RESULTS: A total of 14,213 patients, with 18,029 eligible treatment discontinuation epochs, were identified for 7 therapies. Annualized rates of relapse (ARRs) started to increase 2 months after natalizumab cessation (month 2-4 ARR 0.47, 95% CI 0.43-0.51). Commencement of a subsequent therapy within 2-4 months reduced the magnitude of disease reactivation (mean ARR difference: 0.15, 0.08-0.22). After discontinuation of fingolimod, rates of relapse increased overall (month 1-2 ARR: 0.80, 0.70-0.89) and stabilized faster in patients who started a new therapy within 1-2 months (mean ARR difference: 0.14, -0.01 to 0.29). The magnitude of disease reactivation for other therapies was low but reduced further by commencement of another treatment 1-10 months after treatment discontinuation. Predictors of relapse were a higher relapse rate in the year before cessation, female sex, younger age, and higher EDSS score. Commencement of a subsequent therapy reduced both the risk of relapse (HR 0.76, 95% CI 0.72-0.81) and disability accumulation (0.73, 0.65-0.80). DISCUSSION: The rate of disease reactivation after treatment cessation differs among MS treatments, with the peaks of relapse activity ranging from 1 to 10 months in untreated cohorts that discontinued different therapies. These results suggest that untreated intervals should be minimized after stopping antitrafficking therapies (natalizumab and fingolimod). CLASSIFICATION OF EVIDENCE: This study provides Class III that disease reactivation occurs within months of discontinuation of MS disease-modifying therapies. The risk of disease activity is reduced by commencement of a subsequent therapy.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Roos I, Malpas C, Leray E, et al. Disease Reactivation After Cessation of Disease-Modifying Therapy in Patients With Relapsing-Remitting Multiple Sclerosis. Neurology. 2022. PMID: 35977837. doi:10.1212/WNL.0000000000201029

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。